Eli Lilly enters the back half of May with short sellers in full retreat, a wall of bullish analyst upgrades, and a stock that has clawed back to within striking distance of the $990 level — all while the broader debate shifts from "will tirzepatide work?" to "how fast can it scale?"
The most telling development this week is the speed of short covering. Short interest has fallen 12.5% over the past week and is now down more than 10% over the past month, landing at just 0.82% of the free float. That figure is modest for any large-cap name, and the direction of travel underscores the lack of conviction among bears. After briefly touching close to 1% of float in late April and early May — following the Q1 earnings beat that sent the stock surging 13% in a single session on April 30 — short sellers have been systematically covering. The ORTEX short score, at 29.5, ranks in roughly the 15th percentile of squeeze risk, reflecting a lending market under little stress. Borrow costs at 0.53% are still well within normal territory, and availability remains broad. This is not a stock with meaningful structural short pressure.
Options traders are telling a similarly unremarkable story. The put/call ratio is running at 1.08, almost exactly in line with its 20-day average of 1.08 — a z-score barely distinguishable from zero. For context, the ratio was above 1.20 through much of April when the stock was under pressure from macro noise; that caution has now fully drained out of the market. The 52-week range on the PCR runs from 0.51 to 1.37, which means the current reading is squarely in the defensive middle, neither a contrarian buy signal nor evidence of aggressive call-buying. Positioning, in other words, is neutral.
The Street is the more interesting angle this week. Analysts have been consistently biased upward, with the mean price target at $1,210 against a current price of $989.87 — a gap of roughly 22%. Barclays raised its target to $1,400 on May 5, maintaining an Overweight rating. Morgan Stanley and Bank of America both lifted targets in April. Several firms including Wolfe Research and Guggenheim reiterated positive ratings without moving numbers. The lone dissenter in recent months has been HSBC, which downgraded to Reduce with an $850 target in March — a significant outlier that reflects the bear case: tirzepatide sales trajectory concerns and the risk that forglipron and other pipeline products disappoint. Valuation multiples are ticking up gradually. The trailing P/E is at 25.3, up roughly 2.5 points over the past month, while EV/EBITDA is at 20.6. Neither is stretched by historical growth-pharma standards, and the earnings yield factor — ranking in the 39th percentile — suggests the market is still pricing in strong forward growth rather than paying an extreme multiple on current earnings.
Institutional ownership reinforces the buy-and-hold character of the stock. The top three holders — Lilly Endowment (10.3%), Vanguard (9.2%), and BlackRock (7.5%) — collectively control more than a quarter of outstanding shares. FMR (Fidelity), T. Rowe Price, and Capital Research all added meaningfully in their most recent filings. The Lilly Endowment itself trimmed a modest 309,000 shares in early May — the insider filing tagged as significance 3 out of 10 — which reads more as routine rebalancing than a directional signal. The CFO and two EVPs completed small award-related sales in February, all low-significance transactions. There is no insider selling pattern here worth flagging.
The last earnings print set a high bar. The April 30 Q1 release drove a 13.2% one-day gain and a 14.5% five-day move — an outsized reaction by any measure for a stock of this size. The next event is pencilled in for August 5. Between now and then, the narrative will centre on two things: whether the FDA noise around FAERS adverse event data rattles confidence in Lilly's franchise, and whether the tirzepatide commercial ramp holds pace with consensus estimates projecting EPS of around $44.75 for 2027. EPS momentum scores rank in the 81st percentile on a 30-day basis and the 76th on 90-day, confirming the estimate revision trend is still broadly positive. Peer pharmaceutical names MRK and JNJ were both essentially flat on the week, while AZN added 3.1% — the group as a whole offering no directional headwind for Lilly's near-term setup.
The key variable heading into August is whether the commercial execution story stays clean enough to justify a Street consensus that is still running roughly $220 above where the stock trades today.
See the live data behind this article on ORTEX.
Open LLY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
